JP2016513668A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016513668A5 JP2016513668A5 JP2016502267A JP2016502267A JP2016513668A5 JP 2016513668 A5 JP2016513668 A5 JP 2016513668A5 JP 2016502267 A JP2016502267 A JP 2016502267A JP 2016502267 A JP2016502267 A JP 2016502267A JP 2016513668 A5 JP2016513668 A5 JP 2016513668A5
- Authority
- JP
- Japan
- Prior art keywords
- item
- pharmaceutical composition
- composition according
- subject
- items
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims description 144
- 150000001875 compounds Chemical class 0.000 claims description 125
- 125000005842 heteroatom Chemical group 0.000 claims description 36
- 229910052736 halogen Inorganic materials 0.000 claims description 31
- 150000002367 halogens Chemical class 0.000 claims description 31
- -1 1,2-methylenedioxy Chemical group 0.000 claims description 23
- 230000013629 beta-amyloid clearance Effects 0.000 claims description 23
- 208000002193 Pain Diseases 0.000 claims description 21
- 125000003118 aryl group Chemical group 0.000 claims description 20
- 208000024827 Alzheimer disease Diseases 0.000 claims description 16
- 125000006574 non-aromatic ring group Chemical group 0.000 claims description 16
- 150000003839 salts Chemical class 0.000 claims description 15
- 208000010877 cognitive disease Diseases 0.000 claims description 13
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims description 12
- 125000006714 (C3-C10) heterocyclyl group Chemical group 0.000 claims description 12
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims description 12
- 201000010374 Down Syndrome Diseases 0.000 claims description 12
- 206010044688 Trisomy 21 Diseases 0.000 claims description 12
- 125000001931 aliphatic group Chemical group 0.000 claims description 12
- 102000003802 alpha-Synuclein Human genes 0.000 claims description 12
- 108090000185 alpha-Synuclein Proteins 0.000 claims description 12
- 230000004410 intraocular pressure Effects 0.000 claims description 12
- 230000002708 enhancing effect Effects 0.000 claims description 11
- 125000001072 heteroaryl group Chemical group 0.000 claims description 11
- 230000003920 cognitive function Effects 0.000 claims description 9
- 230000000971 hippocampal effect Effects 0.000 claims description 9
- 230000027928 long-term synaptic potentiation Effects 0.000 claims description 9
- 208000018737 Parkinson disease Diseases 0.000 claims description 8
- 125000004043 oxo group Chemical group O=* 0.000 claims description 8
- 125000000464 thioxo group Chemical group S=* 0.000 claims description 8
- 201000004681 Psoriasis Diseases 0.000 claims description 7
- 208000030886 Traumatic Brain injury Diseases 0.000 claims description 7
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 7
- 230000009529 traumatic brain injury Effects 0.000 claims description 7
- 125000006717 (C3-C10) cycloalkenyl group Chemical group 0.000 claims description 6
- 238000009825 accumulation Methods 0.000 claims description 6
- 125000004429 atom Chemical group 0.000 claims description 6
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 5
- 208000010412 Glaucoma Diseases 0.000 claims description 5
- 239000002671 adjuvant Substances 0.000 claims description 5
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 5
- 229910052794 bromium Inorganic materials 0.000 claims description 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 5
- 230000001965 increasing effect Effects 0.000 claims description 5
- 201000006417 multiple sclerosis Diseases 0.000 claims description 5
- 208000027061 mild cognitive impairment Diseases 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 206010030043 Ocular hypertension Diseases 0.000 claims description 3
- 125000002619 bicyclic group Chemical group 0.000 claims description 3
- 210000004027 cell Anatomy 0.000 claims description 3
- 208000037259 Amyloid Plaque Diseases 0.000 claims description 2
- 208000023105 Huntington disease Diseases 0.000 claims description 2
- 208000009829 Lewy Body Disease Diseases 0.000 claims description 2
- 201000002832 Lewy body dementia Diseases 0.000 claims description 2
- 230000006999 cognitive decline Effects 0.000 claims description 2
- 230000000694 effects Effects 0.000 claims description 2
- 230000003956 synaptic plasticity Effects 0.000 claims description 2
- 208000006673 asthma Diseases 0.000 claims 2
- 230000002490 cerebral effect Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000000638 stimulation Effects 0.000 claims 1
- 208000019553 vascular disease Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 description 96
- 230000004968 inflammatory condition Effects 0.000 description 33
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 18
- 125000000217 alkyl group Chemical group 0.000 description 12
- 108010065805 Interleukin-12 Proteins 0.000 description 7
- 125000005843 halogen group Chemical group 0.000 description 7
- 102000004127 Cytokines Human genes 0.000 description 5
- 108090000695 Cytokines Proteins 0.000 description 5
- 108090000174 Interleukin-10 Proteins 0.000 description 5
- 108090000978 Interleukin-4 Proteins 0.000 description 5
- 230000002757 inflammatory effect Effects 0.000 description 5
- 230000036470 plasma concentration Effects 0.000 description 5
- 206010039073 rheumatoid arthritis Diseases 0.000 description 5
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 description 4
- 201000009273 Endometriosis Diseases 0.000 description 4
- 125000001624 naphthyl group Chemical group 0.000 description 4
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 3
- 201000001320 Atherosclerosis Diseases 0.000 description 3
- 206010009900 Colitis ulcerative Diseases 0.000 description 3
- 208000011231 Crohn disease Diseases 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 102000003816 Interleukin-13 Human genes 0.000 description 3
- 108090000176 Interleukin-13 Proteins 0.000 description 3
- 102000013691 Interleukin-17 Human genes 0.000 description 3
- 108050003558 Interleukin-17 Proteins 0.000 description 3
- 102000000704 Interleukin-7 Human genes 0.000 description 3
- 108010002586 Interleukin-7 Proteins 0.000 description 3
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 3
- 208000036824 Psoriatic arthropathy Diseases 0.000 description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 208000004296 neuralgia Diseases 0.000 description 3
- 208000021722 neuropathic pain Diseases 0.000 description 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 2
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 description 2
- 125000006701 (C1-C7) alkyl group Chemical group 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- 208000030961 allergic reaction Diseases 0.000 description 2
- 230000001363 autoimmune Effects 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 230000000770 proinflammatory effect Effects 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 208000000412 Avitaminosis Diseases 0.000 description 1
- 208000037157 Azotemia Diseases 0.000 description 1
- 208000028698 Cognitive impairment Diseases 0.000 description 1
- 208000001640 Fibromyalgia Diseases 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- 206010021135 Hypovitaminosis Diseases 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 208000003456 Juvenile Arthritis Diseases 0.000 description 1
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 206010028391 Musculoskeletal Pain Diseases 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- 208000001738 Nervous System Trauma Diseases 0.000 description 1
- 206010029240 Neuritis Diseases 0.000 description 1
- 208000004983 Phantom Limb Diseases 0.000 description 1
- 206010056238 Phantom pain Diseases 0.000 description 1
- 206010036376 Postherpetic Neuralgia Diseases 0.000 description 1
- 208000004550 Postoperative Pain Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 208000028911 Temporomandibular Joint disease Diseases 0.000 description 1
- 206010045171 Tumour pain Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000005298 acute pain Diseases 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 238000002266 amputation Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 208000019069 chronic childhood arthritis Diseases 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000003821 menstrual periods Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 208000028412 nervous system injury Diseases 0.000 description 1
- 230000000626 neurodegenerative effect Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000006016 thyroid dysfunction Effects 0.000 description 1
- 206010044652 trigeminal neuralgia Diseases 0.000 description 1
- 208000009852 uremia Diseases 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 208000030401 vitamin deficiency disease Diseases 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361780219P | 2013-03-13 | 2013-03-13 | |
| US61/780,219 | 2013-03-13 | ||
| US201361883604P | 2013-09-27 | 2013-09-27 | |
| US61/883,604 | 2013-09-27 | ||
| PCT/US2014/026865 WO2014160502A1 (en) | 2013-03-13 | 2014-03-13 | Uridine nucleoside derivatives, compositions and methods of use |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016513668A JP2016513668A (ja) | 2016-05-16 |
| JP2016513668A5 true JP2016513668A5 (enExample) | 2017-04-13 |
| JP6591957B2 JP6591957B2 (ja) | 2019-10-16 |
Family
ID=51625444
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016502267A Expired - Fee Related JP6591957B2 (ja) | 2013-03-13 | 2014-03-13 | ウリジンヌクレオシド誘導体、組成物および使用方法 |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US10544183B2 (enExample) |
| EP (2) | EP3449925B1 (enExample) |
| JP (1) | JP6591957B2 (enExample) |
| KR (1) | KR102304242B1 (enExample) |
| CN (1) | CN105407898B (enExample) |
| AU (1) | AU2014243707B2 (enExample) |
| CA (1) | CA2904180C (enExample) |
| DK (1) | DK2968385T3 (enExample) |
| EA (1) | EA034135B9 (enExample) |
| ES (1) | ES2684368T3 (enExample) |
| HU (1) | HUE039871T2 (enExample) |
| IL (1) | IL241172B (enExample) |
| PL (1) | PL2968385T3 (enExample) |
| PT (1) | PT2968385T (enExample) |
| SI (1) | SI2968385T1 (enExample) |
| TW (1) | TWI640533B (enExample) |
| WO (1) | WO2014160502A1 (enExample) |
| ZA (1) | ZA201507045B (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6162125B2 (ja) | 2011-09-30 | 2017-07-12 | タフツ・ユニバーシティ | 神経変性障害を処置するためのウリジン二リン酸誘導体、組成物および方法 |
| AU2013323188B2 (en) | 2012-09-28 | 2018-04-19 | Tufts University | Uridine diphosphate derivatives, prodrugs, compositions and uses thereof |
| AR095442A1 (es) | 2013-03-13 | 2015-10-14 | Univ Tufts | Derivados de nucleósido de uridina, composiciones y métodos de uso |
| PT2968385T (pt) | 2013-03-13 | 2018-10-09 | Univ Tufts | Derivados nucleósidos de uridina, composições e métodos de uso |
| CA3020490A1 (en) | 2016-04-21 | 2017-10-26 | Astrocyte Pharmaceuticals, Inc. | Compounds and methods for treating neurological and cardiovascular conditions |
| KR102791276B1 (ko) | 2018-02-09 | 2025-04-08 | 아스트로사이트 파마슈티컬스, 인코포레이티드 | 중독 및 관련 장애를 치료하기 위한 화합물 및 방법 |
| EA202190576A1 (ru) | 2018-09-26 | 2021-09-03 | Астросайт Фармасьютикалс, Инк. | Полиморфные соединения и их применение |
| US12285182B2 (en) | 2018-10-10 | 2025-04-29 | Innova Vascular, Inc. | Devices and methods for removing an embolus |
| US20220195056A1 (en) * | 2019-08-07 | 2022-06-23 | Icahn School Of Medicine At Mount Sinai | Method of treating keloids |
| CN116437930A (zh) * | 2020-10-30 | 2023-07-14 | 上海岸阔医药科技有限公司 | 尿苷衍生物在制备药物中的应用 |
| WO2022266027A1 (en) * | 2021-06-15 | 2022-12-22 | Steven Baranowitz | Prevention and treatment of post-infection neurological disorders and clotting/thrombotic disorders |
| CN116712448A (zh) * | 2022-11-11 | 2023-09-08 | 上海市皮肤病医院 | 一种治疗银屑病的药物 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0621073B2 (ja) | 1986-03-06 | 1994-03-23 | 日水製薬株式会社 | 中枢抑制剤 |
| JP3032053B2 (ja) | 1991-09-06 | 2000-04-10 | 日水製薬株式会社 | ウリジン誘導体及びこれを含有する医薬 |
| US5962459A (en) | 1996-05-28 | 1999-10-05 | Polifarma S.P.A. | Therapeutic active agent for treatment of neuron degenerative diseases |
| EP1011688B1 (en) * | 1997-08-29 | 2005-02-02 | The University of North Carolina at Chapel Hill | Use of uridine 5'-diphosphate and analogs thereof for the treatment of lung diseases |
| US20060069061A1 (en) | 1998-07-31 | 2006-03-30 | Dick Wurtman | Compositions containing uridine and choline, and methods utilizing same |
| US20070004670A1 (en) | 1998-07-31 | 2007-01-04 | Richard Wurtman | Compositions containing citicoline, and methods of use thereof |
| US8518882B2 (en) | 1998-07-31 | 2013-08-27 | Massachusetts Institute Of Technology | Methods and compositions for ameliorating or inhibiting decline in memory or intelligence or improving same |
| US20050203053A1 (en) | 1999-07-30 | 2005-09-15 | Wurtman Richard J. | Uridine administration improves phosphatide synthesis, synaptic transmission and cogntive function |
| ES2477568T3 (es) | 1998-07-31 | 2014-07-17 | Massachusetts Institute Of Technology | Uso de uridina en combinación con colina para el tratamiento de trastornos de la memoria |
| US8143234B2 (en) | 1998-07-31 | 2012-03-27 | Massachusetts Institute Of Technology | Uridine administration improves phosphatide synthesis, synaptic transmission and cognitive function |
| US8314064B2 (en) | 1998-07-31 | 2012-11-20 | Massachusetts Institute Of Technology | Uridine administration stimulates membrane production |
| GB0004297D0 (en) | 2000-02-23 | 2000-04-12 | Ucb Sa | 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses |
| US6875751B2 (en) | 2000-06-15 | 2005-04-05 | Idenix Pharmaceuticals, Inc. | 3′-prodrugs of 2′-deoxy-β-L-nucleosides |
| US20050074819A1 (en) | 2003-10-01 | 2005-04-07 | Japan Health Sciences Foundation | Screening method of drug for treatment of neuropathic pain |
| WO2005122767A1 (en) | 2004-06-10 | 2005-12-29 | Mclean Hospital Corporation | Pyrimidines, such as uridine, in treatments for patients with bipolar disorder |
| CN102600199A (zh) * | 2004-09-15 | 2012-07-25 | 麻省理工学院 | 含有尿苷的组合物及使用其的方法 |
| US7851456B2 (en) | 2005-06-29 | 2010-12-14 | Inspire Pharmaceuticals, Inc. | P2Y6 receptor agonists for treating lung diseases |
| CN101237772A (zh) * | 2005-06-29 | 2008-08-06 | 印斯拜尔药品股份有限公司 | 用于治疗肺病的p2y6受体激动剂 |
| JP5513135B2 (ja) | 2007-03-19 | 2014-06-04 | カスケード プロドラッグ インコーポレイテッド | マンニッヒ塩基ｎ−オキシド薬物 |
| US7964580B2 (en) | 2007-03-30 | 2011-06-21 | Pharmasset, Inc. | Nucleoside phosphoramidate prodrugs |
| AU2009298802A1 (en) | 2008-09-23 | 2010-04-08 | Alnylam Pharmaceuticals, Inc. | Chemical modifications of monomers and oligonucleotides with cycloaddition |
| IT1398378B1 (it) | 2010-02-22 | 2013-02-22 | Omikron Italia S R L | Citicolina per il trattamento del glaucoma e dell'ipertensione oculare. |
| CN103339136A (zh) * | 2010-12-01 | 2013-10-02 | 巴伊兰大学 | 尿苷二-或三-磷酸衍生物以及其用途 |
| JP6162125B2 (ja) * | 2011-09-30 | 2017-07-12 | タフツ・ユニバーシティ | 神経変性障害を処置するためのウリジン二リン酸誘導体、組成物および方法 |
| AU2013323188B2 (en) | 2012-09-28 | 2018-04-19 | Tufts University | Uridine diphosphate derivatives, prodrugs, compositions and uses thereof |
| AR095442A1 (es) | 2013-03-13 | 2015-10-14 | Univ Tufts | Derivados de nucleósido de uridina, composiciones y métodos de uso |
| PT2968385T (pt) | 2013-03-13 | 2018-10-09 | Univ Tufts | Derivados nucleósidos de uridina, composições e métodos de uso |
-
2014
- 2014-03-13 PT PT14775026T patent/PT2968385T/pt unknown
- 2014-03-13 CN CN201480023822.XA patent/CN105407898B/zh not_active Expired - Fee Related
- 2014-03-13 EP EP18173639.8A patent/EP3449925B1/en active Active
- 2014-03-13 US US14/775,426 patent/US10544183B2/en not_active Expired - Fee Related
- 2014-03-13 CA CA2904180A patent/CA2904180C/en active Active
- 2014-03-13 WO PCT/US2014/026865 patent/WO2014160502A1/en not_active Ceased
- 2014-03-13 SI SI201430843T patent/SI2968385T1/sl unknown
- 2014-03-13 TW TW103109174A patent/TWI640533B/zh not_active IP Right Cessation
- 2014-03-13 EA EA201591598A patent/EA034135B9/ru unknown
- 2014-03-13 DK DK14775026.9T patent/DK2968385T3/en active
- 2014-03-13 KR KR1020157028543A patent/KR102304242B1/ko not_active Expired - Fee Related
- 2014-03-13 EP EP14775026.9A patent/EP2968385B1/en active Active
- 2014-03-13 JP JP2016502267A patent/JP6591957B2/ja not_active Expired - Fee Related
- 2014-03-13 ES ES14775026T patent/ES2684368T3/es active Active
- 2014-03-13 HU HUE14775026A patent/HUE039871T2/hu unknown
- 2014-03-13 PL PL14775026T patent/PL2968385T3/pl unknown
- 2014-03-13 AU AU2014243707A patent/AU2014243707B2/en not_active Ceased
-
2015
- 2015-09-03 IL IL241172A patent/IL241172B/en active IP Right Grant
- 2015-09-22 ZA ZA2015/07045A patent/ZA201507045B/en unknown
-
2020
- 2020-01-27 US US16/773,406 patent/US11124536B2/en not_active Expired - Fee Related
-
2021
- 2021-08-12 US US17/400,515 patent/US20220135611A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016513668A5 (enExample) | ||
| JP2015532289A5 (enExample) | ||
| US11248000B2 (en) | Quinazoline and indole compounds to treat medical disorders | |
| US11649223B2 (en) | Amino compounds for treatment of immune and inflammatory disorders | |
| US11649229B2 (en) | Amide compounds for treatment of immune and inflammatory disorders | |
| US10000516B2 (en) | Phosphonate compounds for treatment of medical disorders | |
| EP3985002B1 (en) | Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders | |
| US10385097B2 (en) | Ether compounds for treatment of medical disorders | |
| JP2014528418A5 (enExample) | ||
| WO2017035411A1 (en) | Ether compounds for treatment of immune and inflammatory disorders | |
| WO2017035413A2 (en) | Carbamate, ester, and ketone compounds for treatment of immune and inflammatory disorders | |
| WO2017035408A1 (en) | Compounds for treatment of immune and inflammatory disorders | |
| WO2017035418A1 (en) | Disubstituted compounds for treatment of immune and inflammatory disorders | |
| WO2017035417A1 (en) | Phosphonate compounds for treatment of immune and inflammatory disorders | |
| TW201718551A (zh) | 用於治療醫學病症之醯胺化合物 | |
| WO2017035351A1 (en) | Amino compounds for treatment of medical disorders | |
| WO2017035415A1 (en) | Alkyne compounds for treatment of immune and inflammatory disorders | |
| WO2017035352A1 (en) | Carbamate, ester, and ketone compounds for treatment of medical disorders | |
| WO2017035360A1 (en) | Compounds for the treatment of medical disorders | |
| WO2017035348A1 (en) | Alkyne compounds for treatment of medical disorders | |
| WO2017035361A1 (en) | Disubstituted compounds for the treatment of medical disorders | |
| JP2018035197A5 (enExample) | ||
| US11814391B2 (en) | Macrocyclic compounds for the treatment of medical disorders | |
| JP2015510941A5 (enExample) | ||
| RU2018144774A (ru) | Антагонист trpv4 |